Global Soliris (Eculizumab) 麻豆原创 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR092411456

Publication Date:

September 18, 2024

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
The global Soliris (Eculizumab) market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
In Asia-Pacific, Japan is the largest Soliris (Eculizumab) market with about 32% market share. China is follower, accounting for about 25% market share.The key manufacturers are Alexion etc.
This report is a detailed and comprehensive analysis for global Soliris (Eculizumab) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Soliris (Eculizumab) market size and forecasts, in consumption value ($ Million), 2019-2030
Global Soliris (Eculizumab) market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Soliris (Eculizumab) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Soliris (Eculizumab) market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Soliris (Eculizumab)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Soliris (Eculizumab) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Alexion, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Soliris (Eculizumab) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Soliris (Eculizumab) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Plasma Exchange
Plasma Infusion
麻豆原创 segment by Application
PNH
aHUS
Others
麻豆原创 segment by players, this report covers
Alexion
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Soliris (Eculizumab) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Soliris (Eculizumab), with revenue, gross margin, and global market share of Soliris (Eculizumab) from 2019 to 2024.
Chapter 3, the Soliris (Eculizumab) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Soliris (Eculizumab) market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Soliris (Eculizumab).
Chapter 13, to describe Soliris (Eculizumab) research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Soliris (Eculizumab) by Type
1.3.1 Overview: Global Soliris (Eculizumab) 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Soliris (Eculizumab) Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Plasma Exchange
1.3.4 Plasma Infusion
1.4 Global Soliris (Eculizumab) 麻豆原创 by Application
1.4.1 Overview: Global Soliris (Eculizumab) 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 PNH
1.4.3 aHUS
1.4.4 Others
1.5 Global Soliris (Eculizumab) 麻豆原创 Size & Forecast
1.6 Global Soliris (Eculizumab) 麻豆原创 Size and Forecast by Region
1.6.1 Global Soliris (Eculizumab) 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Soliris (Eculizumab) 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Soliris (Eculizumab) 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Soliris (Eculizumab) 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Soliris (Eculizumab) 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Soliris (Eculizumab) 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Soliris (Eculizumab) 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Alexion
2.1.1 Alexion Details
2.1.2 Alexion Major Business
2.1.3 Alexion Soliris (Eculizumab) Product and Solutions
2.1.4 Alexion Soliris (Eculizumab) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Alexion Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Soliris (Eculizumab) Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Soliris (Eculizumab) by Company Revenue
3.2.2 Top 3 Soliris (Eculizumab) Players 麻豆原创 Share in 2023
3.2.3 Top 6 Soliris (Eculizumab) Players 麻豆原创 Share in 2023
3.3 Soliris (Eculizumab) 麻豆原创: Overall Company Footprint Analysis
3.3.1 Soliris (Eculizumab) 麻豆原创: Region Footprint
3.3.2 Soliris (Eculizumab) 麻豆原创: Company Product Type Footprint
3.3.3 Soliris (Eculizumab) 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Soliris (Eculizumab) Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Soliris (Eculizumab) 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Soliris (Eculizumab) Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Soliris (Eculizumab) 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Soliris (Eculizumab) Consumption Value by Type (2019-2030)
6.2 North America Soliris (Eculizumab) 麻豆原创 Size by Application (2019-2030)
6.3 North America Soliris (Eculizumab) 麻豆原创 Size by Country
6.3.1 North America Soliris (Eculizumab) Consumption Value by Country (2019-2030)
6.3.2 United States Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Soliris (Eculizumab) Consumption Value by Type (2019-2030)
7.2 Europe Soliris (Eculizumab) Consumption Value by Application (2019-2030)
7.3 Europe Soliris (Eculizumab) 麻豆原创 Size by Country
7.3.1 Europe Soliris (Eculizumab) Consumption Value by Country (2019-2030)
7.3.2 Germany Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Soliris (Eculizumab) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Soliris (Eculizumab) Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Soliris (Eculizumab) 麻豆原创 Size by Region
8.3.1 Asia-Pacific Soliris (Eculizumab) Consumption Value by Region (2019-2030)
8.3.2 China Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Soliris (Eculizumab) Consumption Value by Type (2019-2030)
9.2 South America Soliris (Eculizumab) Consumption Value by Application (2019-2030)
9.3 South America Soliris (Eculizumab) 麻豆原创 Size by Country
9.3.1 South America Soliris (Eculizumab) Consumption Value by Country (2019-2030)
9.3.2 Brazil Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Soliris (Eculizumab) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Soliris (Eculizumab) Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Soliris (Eculizumab) 麻豆原创 Size by Country
10.3.1 Middle East & Africa Soliris (Eculizumab) Consumption Value by Country (2019-2030)
10.3.2 Turkey Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Soliris (Eculizumab) 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Soliris (Eculizumab) 麻豆原创 Drivers
11.2 Soliris (Eculizumab) 麻豆原创 Restraints
11.3 Soliris (Eculizumab) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Soliris (Eculizumab) Industry Chain
12.2 Soliris (Eculizumab) Upstream Analysis
12.3 Soliris (Eculizumab) Midstream Analysis
12.4 Soliris (Eculizumab) Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Alexion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.